Key Highlights

  • Net loss of USD 0.99 per share was wider than the USD 0.89 loss in the consensus estimate.
  • Total revenue of USD 3.4 million missed the USD 4.2 million consensus estimate and the year-ago USD 12.5 million.
  • VIZZ product sales of USD 2.6 million rose about 50% from the second quarter on over 38,000 paid prescriptions.
  • A reorganization targets 2027 operating expenses of USD 70 million to USD 75 million, excluding stock-based compensation.

LENZ Therapeutics, Inc. (NASDAQ:LENZ), the presbyopia eye-drop company, reported a third-quarter 2026 net loss of USD 31.0 million, or USD 0.99 per share, compared with a loss of USD 16.7 million, or USD 0.59 per share, a year earlier. The result was below a consensus estimate of a USD 0.89 loss per share. Total revenue was USD 3.4 million, under a consensus estimate of USD 4.2 million, and well below the USD 12.5 million posted in the prior-year quarter, which consisted entirely of license payments.

Current-quarter revenue combined USD 2.6 million of VIZZ product sales with USD 0.8 million of license revenue. Product sales had no prior-year comparison because the drug had not yet launched. Selling, general and administrative expenses rose to USD 35.8 million from USD 27.6 million on higher marketing, advertising, sales infrastructure and headcount, and there was no research and development expense against USD 3.8 million a year ago.

Prescription Trends and Distribution

VIZZ product sales rose about 50% from the second quarter, and paid prescriptions grew about 51% to more than 38,000, with gains in both ePharmacy and retail channels. A telehealth prescribing option launched in July accounted for more than 50% of the incremental prescriptions over the second quarter. More than 60% of ePharmacy patients have bought more than one monthly pack, and refill rates average five packs per year for patients who started in the fourth quarter of 2025 and first quarter of 2026.

More than 15,000 unique eye care professionals have prescribed VIZZ since launch, and over 75% of them prescribed more than once. A nationwide television campaign began in July. Internationally, filings in Saudi Arabia, Malaysia and Vietnam brought the count of ex-U.S. regulatory submissions to eleven.

Reorganization and Leadership Change

The company is implementing a reorganization in the fourth quarter that shifts resources toward consumer marketing. It projects 2027 annualized operating expenses to fall by more than 50%, to roughly USD 70 million to USD 75 million excluding stock-based compensation, and estimates one-time net restructuring charges of about USD 5 million.

CEO Eef Schimmelpennink steps down effective December 1, 2026 and remains a strategic advisor into 2027. The company's current chief financial officer becomes interim president and chief executive officer on that date. Cash, cash equivalents and marketable securities stood at USD 197.3 million at September 30, 2026, compared with about USD 292.3 million at the end of 2025.

Disclosures to Follow

Four items frame the next report. The first is prescription momentum, with management citing growth carrying into the fourth quarter from the 38,000 paid prescriptions in the third. The second is the reorganization, scheduled for completion in the fourth quarter with about USD 5 million in charges. The third is leadership, with the interim handover set for December 1 and a conference call on October 29. The fourth is liquidity: nine-month net loss was USD 104.4 million, and cash declined by roughly USD 95 million over that span.